An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder

Wayne A Hening; Richard P Allen; Christopher J Earley; Daniel L Picchietti; Michael H Silber; Restless Legs Syndrome Task Force of the Standards of Practice Committee of the American Academy of Sleep Medicine

doi:10.1093/sleep/27.3.560

An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder

Sleep. 2004 May 1;27(3):560-83. doi: 10.1093/sleep/27.3.560.

Authors

Wayne A Hening¹, Richard P Allen, Christopher J Earley, Daniel L Picchietti, Michael H Silber; Restless Legs Syndrome Task Force of the Standards of Practice Committee of the American Academy of Sleep Medicine

Affiliation

¹ Johns Hopkins Sleep Disorders Center, Johns Hopkins Bayview Medical Center, Baltimore, MD, USA.

PMID: 15164915
DOI: 10.1093/sleep/27.3.560

Abstract

This paper reviews evidence from April, 1998 through April 2002 for the dopaminergic treatment of the restless legs syndrome (RLS) and periodic limb movement disorder (PLMD). There has been increased study of dopaminergic agents for the treatment of these conditions since publication of a review paper and practice parameters that covered all types of medical treatment of RLS and PLMD in 1999. For this reason, the Restless Legs Syndrome Task Force and the Standards of Practice Committee decided to update the evidence on dopaminergic treatment of these conditions. This paper reviews the literature on levodopa, dopaminergic agonists (pergolide, pramipexole, ropinirole, talipexole, cabergoline, piribidel, DHEC), and other dopaminergic agents (amantadine, selegiline).

Publication types

Review

MeSH terms

Dopamine Agonists / therapeutic use*
Double-Blind Method
Female
Humans
Male
Nocturnal Myoclonus Syndrome / drug therapy*
Nocturnal Myoclonus Syndrome / physiopathology
Parkinson Disease / epidemiology
Restless Legs Syndrome / drug therapy*
Restless Legs Syndrome / physiopathology

Substances

Dopamine Agonists